Li and Sun (2023) reported that a QLQXC (1.2 g/time, 3 times/d) combined with levosimendan for 3 months could reduce the levels of NT-pro BNP, cTnI, cTnTLN, HA and PCIII in elderly patients with CHF and can also reduce the expression of serum CRP, IL-6 and TNF-α. This evidence concerns the gene IL6 and congestive heart failure.